American biotech firm Novavax said on May 10 (2021) that it had positive results from preclinical studies of a shot combining its influenza and Covid-19 vaccine candidates.
The study, now on a preprint server and awaiting peer review, showed that the shot produced strong levels of antibodies against both diseases in ferrets and hamsters.
Already a subscriber? Log in.
Get 30% off with our ads free Premium Plan!
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!